ArticleEClinicalMedicine2023

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).

Yuanyuan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.